MZTF:TASEMizrahi Tefahot Bank Ltd Analysis
Data as of 2026-08-02 - not real-time
ILA 22,770.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Mizrahi Tefahot Bank trades at 22,770 ILA, well below its DCF fair value of 70,531 ILA, implying an upside of roughly 13% and a clear undervalued positioning. The stock carries a modest P/E of 10.7 versus the industry average of 18, a robust dividend yield of 4.18% and a payout ratio under 50%, suggesting attractive income potential. Technicals show a bullish MACD histogram (+46) and a RSI of 63, hinting at short‑term momentum but also edging toward overbought territory. Volume is on a decreasing trend, and the price sits just below the 200‑day SMA (22,724) while comfortably above the 20‑day and 50‑day SMAs, indicating a neutral to slightly bearish short‑term bias. The beta of only 0.04 and a 30‑day volatility of ~28% point to low systematic risk but noticeable price swings. Overall, the combination of deep valuation discount, solid dividend, and defensive risk profile makes the stock compelling for value‑oriented investors.
The risk landscape is tempered by the bank’s strong balance sheet—large cash reserves, negligible debt‑to‑equity and a healthy ROE of 16%—yet regulatory and geographic considerations in Israel remain medium‑level concerns. Liquidity is adequate despite a falling volume trend, and the currency exposure is limited to the Israeli shekel, keeping currency risk low. Given these fundamentals and technical signals, the recommendation leans toward buying for the medium and long term, while a short‑term hold is prudent until price approaches the near‑term resistance of 23,100 ILA.
The risk landscape is tempered by the bank’s strong balance sheet—large cash reserves, negligible debt‑to‑equity and a healthy ROE of 16%—yet regulatory and geographic considerations in Israel remain medium‑level concerns. Liquidity is adequate despite a falling volume trend, and the currency exposure is limited to the Israeli shekel, keeping currency risk low. Given these fundamentals and technical signals, the recommendation leans toward buying for the medium and long term, while a short‑term hold is prudent until price approaches the near‑term resistance of 23,100 ILA.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD but RSI approaching overbought
- Price near short‑term resistance at 23,100 ILA
- Decreasing volume trend
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF valuation indicates ~13% upside
- Strong dividend yield and sustainable payout
- Low beta and defensive banking sector
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Robust balance sheet with high cash and minimal leverage
- Consistent earnings and ROE above 15%
- Long‑term undervaluation relative to fair value
Key Metrics & Analysis
Financial Health
Revenue Growth0.30%
Profit Margin38.82%
P/E Ratio10.7
ROE16.47%
ROA1.10%
P/B Ratio1.7
Op. Cash FlowILA14.6B
Industry P/E18.0
Technical Analysis
TrendNeutral
RSI62.7
SupportILA 19,690.00
ResistanceILA 23,100.00
MA 20ILA 21,950.00
MA 50ILA 21,065.20
MA 200ILA 22,724.40
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair ValueILA 70,530.84
Target PriceILA 25,708.33
Upside/Downside12.90%
GradeUndervalued
TypeValue
Dividend Yield4.18%
Risk Assessment
Beta0.04
Volatility27.79%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.